Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAIC plus lenvatinib bridging therapy before liver transplantation for hepatocellular carcinoma beyond Milan criteria
ChiCTR2100052881Phase 4Recruiting
- Sponsor
- The Third Affiliated Hospital of Sun Yat-sen University
- Start
- Nov 2021
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of lenvatinib, oxaliplatin, folinic acid and fluorouracil in hepatocellular carcinoma (HCC), sponsored by The Third Affiliated Hospital of Sun Yat-sen University. Primary endpoints: Routine blood test, Abdominal CT/MR scan and 8 more. Started Nov 2021; status: recruiting.
02
Drugs
lenvatiniboxaliplatinfolinic acidfluorouracil
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2100052881.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100052881.